[1]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851-854.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(7):851-854.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
点击复制

非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年7期
页码:
851-854
栏目:
临床研究
出版日期:
2020-07-05

文章信息/Info

Title:
Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect
作者:
彭 峰; 彭奕华; 张宏华; 杨印楼
广东省韶关市粤北人民医院呼吸内科(韶关512026)
Author(s):
PENG Feng; PENG Yihua; ZHANG Honghua; et al.
Department of Respiratory Medicine,Yuebei People's Hospital,Shaoguan City,Guangdong Province(Shaoguan 512026)
关键词:
非小细胞肺癌;  化疗;  糖类抗原125;  肿瘤异常蛋白;  对比研究
Keywords:
Non small cell lung cancer;  Chemotherapy;  Carbohydrate antigen 125;  Tumor abnormality protein;  Comparative study
分类号:
R734.2
DOI:
DOI:10.3969/j.issn.10007377.2020.07.023
文献标志码:
A
摘要:
目的:探讨非小细胞肺癌(NSCLC)化疗前后血清糖类抗原125(CA125)、肿瘤异常蛋白(TAP)水平变化及其与疗效的关系。方法:选取NSCLC患者120例作为NSCLC组,同期选取体检中心健康人员60例作为健康组,检查所有人员血清CA125、TAP水平,分析血清CA125、TAP水平与疗效的关系。结果:NSCLC组血清CA125、TAP水平明显高于健康组,比较差异有统计学意义(P<0.05); NSCLC组化疗后,完全缓解(CR)24 例(20.00%)、部分缓解(PR)54例(45.00%)、稳定(SD)36例(30.00%)、进展(PD)6例(5.00%); CR、PR、PD患者化疗前后血清CA125、TAP水平及其下降比比较,差异有统计学意义(P<0.05),SD患者化疗前后血清CA125、TAP水平及其下降比比较,差异无统计学意义(P>0.05); ROC曲线分析结果显示,在评估NSCLC化疗有效性的敏感度、特异度、准确度方面,CA125下降比以>27%为临界值时为88.46%、69.48%、81.67%,TAP下降比以>18%为临界值时为85.90%、69.48%、80.00%,TAP联合CA125为96.15%、90.48%、94.17%,TAP联合CA125明显高于二者单独时,差异有统计学意义(P<0.05)。结论:NSCLC化疗前后血清CA125、TAP水平变化与疗效有关,检测血清CA125、TAP水平可作为评估患者化疗疗效的重要指标,且二者联合时具有更佳的效能。
Abstract:
Objective:To discuss the changes of serum carbohydrate antigen 125(CA125)and tumor abnormal protein(TAP)levels before and after chemotherapy for non-small cell lung cancer(NSCLC)and their relationship with curative effect. Methods:120 patients with NSCLC were selected as NSCLC group. Meanwhile,60 healthy persons in the physical examination center were selected as health group. The serum levels of CA125 and TAP were examined,and the relationship between serum CA125 and TAP levels and curative effect was analyzed. Results:Serum CA125 and TAP levels in NSCLC group were significantly higher than those in health group,and the difference was statistically significant(P<0.05). After chemotherapy,in group NSCLC,24 cases(20.00%)were completely remission(CR),partial remission(PR)was 54 cases(45.00%),stability(SD)was 36 cases(30.00%),progression(PD)was 6 cases(5.00%). The levels of serum CA125 and TAP in patients with CR,PR and PD before and after chemotherapy were compared,and the difference was statistically significant(P<0.05). The serum levels of CA125 and TAP in SD patients before and after chemotherapy were compared,and the difference was not statistically significant(P>0.05). ROC curve analysis showed that in terms of sensitivity,specificity and accuracy of evaluating the effectiveness of NSCLC chemotherapy,CA125 was 88.46%,69.48%,81.67% when the critical value was >27%,and TAP was 85.90%,69.48%,80.00% when the critical value was >18%,and the combination of CA125 and TAP was 96.15%、90.48%、94.17%(P<0.05). Conclusions:The changes of serum CA125 and TAP levels were related to the curative effect before and after NSCLC chemotherapy. The detection of serum CA125 and TAP levels can be used as an important indicator for evaluating the efficacy of chemotherapy in patients,and the combination of the two has better performance,which is worthy of further clinical promotion.

参考文献/References:

[1] 王晓东,张 涛,崔 凯,等. 术前外周血小板计数与淋巴细胞计数比值对非小细胞肺癌根治术后并辅助化疗患者预后的影响[J]. 陕西医学杂志,2019,48(9):1147-1150.
[2] Gadgeel SM,Gandhi L,Riely GJ,et al. Safety and activityof alectinib against systemic disease and brain metastases inpatients with crizotinib-resistant ALK - re arrange d non-smallcelllung cancer(AF-002JG):results from the dose-findingportion of a phase 1/2 study [J]. Lancet Oncol,2014,15(10):1119-1128.
[3] 赵美华,张 郡,刘华亮.术前CT联合超声和CA125检测对卵巢癌的诊断价值[J].广东医学,2014,35(2):250-251.
[4] Pfaendlert KS,Tewari KS. Changing paradigms in thesystemic treatment of advanced cervical cancer[J]. Am J Obstet Gynecol,2016,214(1):22-30.
[5] Lelj-Garolla B,Kumano M,Beraldi E,et al. Hsp27 inhibition with OGX-427 sensitizes non-Small cell lung cancer cells to arlotinib and chemotherapy [J]. Molecular Cancer Therapeutics,2015,14(5):1107-1116.
[6] 张百红,岳红云. 实体瘤疗效评价标准简介[J]. 国际肿瘤学杂志,2016,43(11):845-847.
[7] Shaw AT,Kim DW,Mehra R,et al. Ceritinib in ALK-rearrangednon-small-cell lung cancer [J]. N Engl J Med,2014,370(13):1189-1197.
[8] Ruyssen-Witrand A,Lukas C,Nigon D,et al. Association of IL-2RA and IL-2RB genes with erosive status in early rheumatoid arthritis patients(ESPOIR and RMP cohorts)[J]. Joint Bone Spine,2014,81(34):225-234.
[9] 任东峰,孙国芳. 六君祛痰解毒汤联合化疗治疗非小细胞肺癌疗效及对患者血管内皮生长因子的影响[J]. 陕西中医,2020,41(1):63-65.
[10] 林秋菊,罗 健,江 旭,等.奈达铂或顺铂联合多西他赛治疗晚期非小细胞肺癌的临床观察[J].中国肿瘤临床与康复,2014,21(11):1337-1339.
[11] Chen Y,Gao SG,Chen JM,et al.Serum CA242,CA199,CA125,CEA and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients[J].Cell Biochem Biophys,2015,71(3):1287-1291.
[12] 王 玲,申 鸿. 癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究[J]. 陕西医学杂志,2019,48(8):1080-1084.
[13] 许 刚,徐 惠,冯志俊.肿瘤异常蛋白在宫颈癌患者同步放化疗中的变化及临床意义[J].中国现代医学杂志,2018,28(3):87-91.
[14] 薛 珊,查琼芳,赵旭霁,等.CEA、CA125、CYFRA21-1、NSE和SCC对非小细胞肺癌化疗效果及进展评估的价值[J].山东医药,2015,55(25):8-11.
[15] 姜 峰,杜 然.TAP联合Ki-67对判断非小细胞肺癌患者预后的临床意义[J].临床与实验病理学杂志,2017,33(1):104-106.
[16] 王雪冰,李 康.自拟生血方加减联合铂类化疗方案治疗非小细胞肺癌临床疗效分析[J].中华中医药学刊,2017,35(8):2164-2167.
[17] 王 纯,卢宏达.新辅助化疗对局部晚期非小细胞肺癌肿瘤标记物和淋巴细胞亚群的影响[J].重庆医学,2014,43(1):61-63,66.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[3]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(7):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[4]邵渊.上颌窦癌临床特征及治疗[J].陕西医学杂志,2021,50(4):387.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.001]
[5]雷 普,卢红梅,卜小斌,等.新型内分泌联合化疗治疗高危前列腺癌临床研究[J].陕西医学杂志,2021,50(4):454.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.018]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]常瑞霞,可春梅.血小板相关参数和凝血指标在肺癌治疗中的变化及意义[J].陕西医学杂志,2021,50(5):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
　CHANG Ruixia,KE Chunmei.Changes and significance of platelet-related parameters and coagulation indexes in treatment of lung cancer[J].,2021,50(7):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
[8]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(7):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[9]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(7):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[10]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(7):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[11]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(7):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[12]赵 鹏,刘 冬,兰 飞,等.非小细胞肺癌化疗前后血清糖类抗原125、基质金属蛋白酶-9、可溶性程序性死亡配体1水平变化及其与疗效关系研究[J].陕西医学杂志,2022,51(12):1564.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.023]
　ZHAO Peng,LIU Dong,LAN Fei,et al.Changes of serum CA125,MMP-9 and sPD-L1 levels before and after chemotherapy in non-small cell lung cancer and their relationship with therapeutic effect[J].,2022,51(7):1564.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.023]

更新日期/Last Update: 2020-07-28